Recorded device evidence

INFINITY™ OCT System (K163375): indications, design and recorded evidence

The acquired K163375 file contains product-specific indications and users, design and operating principle, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-08. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 33 selected decisions under primary code NKG. 33 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

Calendar elapsed days: lower quartile 55.0, median 58.0, upper quartile 108.0. These are recorded calendar differences, not active FDA review time.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K163375 ↗ · this pageINFINITY™ OCT System2016-12-01 → 2017-08-21263Traditional
K254260 ↗The VEGA Cervical Screw System2025-12-29 → 2026-09-17262Traditional
K253195 ↗TAURUS Posterior Occipital-Cervico-Thoracic Spinal Systems2025-09-26 → 2026-06-02249Traditional
K254045 ↗CarboClear® Posterior Cervical Screw System; CarboClear® Hybrid Posterior Cervical Screw System2025-12-17 → 2026-03-1689Traditional
K254165 ↗Infinity™ OCT System2025-12-22 → 2026-01-2130Special

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K163375 · PDF page 3 ↗ Source 2

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K163375 · PDF page 5 ↗ Source 3

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K163375 · PDF page 6 ↗ Source 4

In accordance with the Guidance for Industry and FDA Staff - Spinal System 510(k)'s,
        Medtronic has evaluated the subject devices to demonstrate substantial equivalence to
        the identified predicate devices.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK163375 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryINFINITY™ OCT System [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantMedtronic Sofamor Danek USA, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeNKG [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2017-08-21 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2016-12-01 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[44630] · record 03b0a0d15b47593b76f0287fcd333e748eb1bdc7bcf4edd5676d23989fa4c937
  • [5] Complete results array / fda-decision-context:K163375 · record whole dataset partition

FDA 510(k) summary — K163375 ↗

Mon, 04 Sep 2017 13:30:54 GMT · retrieved 2026-10-08

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot fff81140ea07eda07afcd0083baabd4784dc907c7fee13a83082b95dceb7600b

  • [2] PDF page 3 · record a9faf8377abab3abb0e32e34d3345099080d92583dbd8d693412c1864b537c20
  • [3] PDF page 5 · record 60baf45b4eda201d55c061d5cbb5874b6b4be7f5dce4b7ae9cfef742265404db
  • [4] PDF page 6 · record 5917496c847622232dd953a5264509c2727a819bd5d59405db48748c1d329b40

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services